# SynKIR-310 for Relapsed/Refractory B-NHL

> **NCT06544265** · PHASE1 · RECRUITING · sponsor: **Verismo Therapeutics** · enrollment: 36 (estimated)

## Conditions studied

- B Cell Lymphoma
- NHL, Adult
- Mantle Cell Lymphoma
- Relapsed Non-Hodgkin Lymphoma
- Refractory Non-Hodgkin Lymphoma
- Aggressive B-Cell Non-Hodgkin Lymphoma
- Indolent B-Cell Non-Hodgkin Lymphoma
- Follicular Lymphoma
- Marginal Zone Lymphoma
- DLBCL - Diffuse Large B Cell Lymphoma
- HGBL With MYC and BCL2 and/or BCL6 Rearrangements
- High-grade B-cell Lymphoma
- Diffuse Large B Cell Lymphoma
- Large B-cell Lymphoma
- T-Cell/Histiocyte Rich Lymphoma
- Non-hodgkin Lymphoma,B Cell
- Primary Mediastinal Large B-cell Lymphoma (PMBCL)
- Epstein-Barr Virus Positive DLBCL, Nos
- Follicular Lymphoma Grade 3B
- DLBCL (Diffuse Large B-Cell Lymphoma) Associated With Chronic Inflammation
- High Grade B-Cell Lymphoma, Not Otherwise Specified
- Follicular Lymphoma Grade 3
- Marginal Zone Splenic Lymphoma
- DLBCL
- Waldenstrom Macroglobulinemia
- Waldenstrom Macroglobulinaemia

## Interventions

- **BIOLOGICAL:** SynKIR-310

## Key facts

- **NCT ID:** NCT06544265
- **Lead sponsor:** Verismo Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-01
- **Primary completion:** 2028-09
- **Final completion:** 2028-12
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06544265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06544265, "SynKIR-310 for Relapsed/Refractory B-NHL". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06544265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*